CA-INVIVOSCRIBE
A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT).
This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant.
A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population.
Dr. Hourigan, Director of the Virginia Tech FBRI Cancer Research Center in Washington, DC and Principal Investigator of the study, remarked, "This research underscores the value of pre-transplant testing for residual FLT3-ITD in adults with AML. The association of MRD test results with post-transplant outcomes opens up the potential of refining treatment strategies to improve survival."
Moving forward, the study calls for further research to explore alternative approaches for high-risk populations who may not benefit from current standard care protocols.
Dr. Jeff Miller, CEO/CSO at Invivoscribe commented, "We are thrilled to see the remarkable association of clinical outcomes that were so clearly delineated using our research use only test and software. This research study enhances our understanding of AML monitoring and treatment."
About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized research reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies interested in developing and commercializing companion diagnostics, and provides expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization. For additional information, please visit www.invivoscribe.com or contact us at inquiry@invivoscribe.com and follow us on Linked In.
1. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia, Dillon et al, JAMA Oncology, Published online May 2, 2024.
2. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, Dillon et al, JAMA 2023; 329 (9): 745-755
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508192559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Launches Silicon Shoring: an AI-Powered Software Delivery Model to Optimise and Automate the Entire Software Development Life Cycle15.5.2025 11:00:00 CEST | Press release
Reply,a global systems integrator and technology consulting firm, has launched Silicon Shoring, a new software delivery model powered by Artificial Intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515940305/en/ Silicon Shoring is an AI-Powered Software Delivery model designed to optimise and automate the entire Software Development Life Cycle. Silicon Shoring enhances how companies source, build, and manage software by integrating Generative AI agents across the entire Software Development Life Cycle (SDLC) - from requirements and code generation to testing, deployment, operations, and monitoring. The model replaces traditional software development process with a flexible, intelligent, and automated delivery approach, blending AI with human expertise to deliver scalable, high-quality software at speed. Silicon Shoring delivers measurable business value. Reply’s experience demonstrates a significant acceleratio
JPMorganChase to Expand Paris Office Space15.5.2025 10:30:00 CEST | Press release
Firm signs a long term lease on a new building at 37 Place du Marché Saint-Honoré, while retaining its French headquarters at 14 Place VendômeTotalling 16,000 square-metres, this new building will have large open floors and modern amenities across five storeys and a capacity of 1,000 employeesNew office reflects a continued long term commitment to the city, and reflects wider investments in France where the firm has invested over $100 million through business and philanthropic partnerships since 2018 JPMorganChase today announces that it has signed a lease on a new building in Paris at 37 Place du Marché Saint-Honoré as the firm has passed over 1,000 employees in the city. The new office is situated behind the bank’s headquarters at 14 Place Vendôme, and is opposite 21 Place du Marché Saint-Honoré, where the bank also has employees. While this investment will see the firm reduce the buildings it occupies in central Paris from six to just three, overall office space will increase signif
Arion Bank Strengthens Compliance With Volante Technologies’ Payments as a Service15.5.2025 10:16:00 CEST | Press release
Iceland’s leading bank strengthens its modern payments infrastructure and partners with Volante to support long-term innovation and growth Volante Technologies, the global leader in Payments as a Service (PaaS), announced a strategic partnership with Iceland’s leading financial institution, Arion Bank, to modernise and future-proof the bank's payments infrastructure, solidify its regulatory response, and prepare for an increase in transaction volume as part of its growth plan. Arion Bank is one of Iceland's leading financial institutions and the third-largest bank in the country by assets. It offers a wide range of services in retail, corporate, and investment banking, providing smart and reliable financial solutions to individuals and businesses alike. The bank sought to evolve its current payments hub by adopting a modern, API-driven, and scalable solution designed to support multi-rail processing and seamless integration with the emerging payments ecosystem. By partnering with Volan
ITEN and A*STAR IME Announce Breakthrough in Solid-State Battery Integration for Advanced Packaging15.5.2025 09:00:00 CEST | Press release
ITEN, a global leader in micro solid-state batteries, and A*STAR Institute of Microelectronics (A*STAR IME), a leader in advanced packaging research, have announced a groundbreaking achievement for the integration of ITEN’s micro batteries using A*STAR IME’s cutting-edge advanced packaging platform. This milestone paves the way for in-package energy storage solutions, enabling more efficient, compact, and reliable system-in-package (SiP) designs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515958544/en/ Revolutionizing Energy Storage and Advanced Packaging This breakthrough innovation represents a significant leap forward in SiP technology. By embedding ITEN’s high-performance solid-state batteries at the wafer level, ITEN and A*STAR IME have successfully demonstrated integrating non-volatile energy storage directly using advanced packaging. This enables seamless integration, elevating energy efficiency and operational
Equiduct Expands into the Swiss Market15.5.2025 08:00:00 CEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom